ZGNX - Zogenix May Have Tumbled But A Buy Opportunity Has Been Created

Zogenix (ZGNX) had announced results from its phase 3 study treating patients with Lennox-Gastaut Syndrome (LGS). The primary endpoint of the study was met, however, investors were disappointed in that they expected the reduction of monthly seizures to be greater than what was reported. This goes back to FINTEPLA achieving positive results in another rare epilepsy disease known as Dravet Syndrome (DS). From this late-stage study, the company had seen a larger reduction in monthly seizures. The company still has an upcoming FDA review date for FINTEPLA in DS. I believe that